Shachar Shlosberger
Directeur Financier/CFO chez ENLIVEX THERAPEUTICS LTD.
Fortune : 2 551 $ au 31/05/2024
Provenance du réseau au premier degré de Shachar Shlosberger
Entité | Type d'entité | Industrie | |
---|---|---|---|
Public Company | Biotechnology | 19 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Shachar Shlosberger via son réseau personnel
Société | Secteur | Personnes liées | Poste principal |
---|---|---|---|
Thomas Jefferson University | College/University | Corporate Officer/Principal | |
MOLECULAR PHARMACOLOGY (USA), LTD. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Janssen R&D Ireland Ltd. | President | ||
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | Pharmaceuticals: Major | Founder Chief Executive Officer Chief Executive Officer Director/Board Member | |
The General Hospital Corp.
The General Hospital Corp. Hospital/Nursing ManagementHealth Services The General Hospital Corp. provides healthcare services. It offers diagnostic and therapeutic are in every specialty and subspecialty of medicine and surgery. The firm's care center provides cancer, digestive disorders, heart disease, transplantation and vascular medicine services. The company was founded in 1811 and is headquartered in Boston, MA. | Hospital/Nursing Management | Corporate Officer/Principal | |
Flagship Pioneering
Flagship Pioneering Investment ManagersFinance Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts. | Investment Managers | Private Equity Investor | |
The University of Reading | College/University | Graduate Degree | |
Yale University | College/University | Undergraduate Degree | |
Technion-Israel Institute of Technology | College/University | Undergraduate Degree Doctorate Degree | |
The Hebrew University of Jerusalem | College/University | Undergraduate Degree Doctorate Degree | |
Seoul National University | College/University | Graduate Degree | |
Ben-Gurion University of the Negev | College/University | Doctorate Degree | |
Weizmann Institute of Science | College/University | Doctorate Degree Doctorate Degree Doctorate Degree | |
OPKO HEALTH, INC. | Medical/Nursing Services | Corporate Officer/Principal | |
Sidney Kimmel Medical College | College/University | Corporate Officer/Principal | |
GAMIDA CELL LTD. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Institute of Human Virology
Institute of Human Virology Other Consumer ServicesConsumer Services The Institute of Human Virology (IHV) is a research institute located in Baltimore, MD, affiliated with the University of Maryland School of Medicine. The IHV is the first research institute in the US to link basic science, population studies, and clinical trials in an effort to develop new vaccines and treatments for chronic viral diseases such as HIV/AIDS, hepatitis C, hepatitis B, and human papillomavirus infection. The IHV serves approximately 5,000 patients through six Baltimore area clinics and more than 500,000 patients in seven African and two Caribbean nations. The IHV also provides compassionate cutting-edge care and specializes in the treatment of HIV/AIDS and other chronic viral diseases. | Other Consumer Services | Chairman | |
KAHR Medical Ltd.
KAHR Medical Ltd. Pharmaceuticals: MajorHealth Technology KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
CONTRAFECT CORPORATION | Biotechnology | Chief Executive Officer | |
Johnson & Johnson Pharmaceutical Group | Corporate Officer/Principal | ||
Tibotec Pharmaceuticals | Chief Executive Officer | ||
Elastagen Pty Ltd.
Elastagen Pty Ltd. Medical SpecialtiesHealth Technology Elastagen Pty Ltd. produces and develops synthetic human elastin for medical device applications. Its products include skin rejuvenation, scar remodeling, skin tissue repair, wound healing, surgical glues and sealants. The firm developed a Elastatherapy treatments which offer the chance to restore the levels of Elastin in human skin, with benefits anticipated in both medical dermatology and cosmetic applications. The company was founded by Anthony Weiss in 2003 and is headquartered in Sydney, Australia. | Medical Specialties | Director/Board Member | |
COLLPLANT BIOTECHNOLOGIES LTD. | Medical Specialties | Director/Board Member Chairman Director/Board Member | |
Celleron Therapeutics Ltd.
Celleron Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Celleron Therapeutics Ltd. is an oncology company based in Oxford, UK. Celleron has deep relationships with Oxford University and is located on the Oxford Science Park. The British company focuses on the clinical development of new and innovative therapies to treat cancer. Celleron is developing a novel group of clinical products, supported by predictive companion diagnostics, that act through defined molecular mechanisms to prevent cancer cell growth. The company's lead products are currently in clinical trials, and they have a biomarker platform that allows them to identify responsive patients. Celleron Therapeutics Ltd. was founded in 2004, and the CEO is Nick la Thangue. | Pharmaceuticals: Major | Director/Board Member | |
EVELO BIOSCIENCES, INC. | Pharmaceuticals: Major | Director/Board Member | |
Atrogi AB
Atrogi AB BiotechnologyHealth Technology Atrogi AB engages in research and development & sells type 2 diabetes (T2D) with minimal side effects. The company was founded by Tore Bengtsson and Andreas Bhagwani in 2013 and is headquartered in Solna, Sweden. | Biotechnology | Director/Board Member | |
RUBIUS THERAPEUTICS | Biotechnology | Director/Board Member | |
FutuRx Ltd.
FutuRx Ltd. Investment ManagersFinance FutuRx Ltd (FutuRx ) is a venture capital firm founded in 2014. The firm is headquartered in Ness Ziona. | Investment Managers | Consultant / Advisor Human Resources Officer | |
Pavilion Data Systems, Inc.
Pavilion Data Systems, Inc. Packaged SoftwareTechnology Services Pavilion Data Systems, Inc. designs and develops NVMe-oF storage technologies. Its NVMe-over-Fabric Storage Array ingests, processes, stores, and serves an order of magnitude more data for massively-parallel, modern applications. The company was founded by Kiran Malwankar, V. R. Satish, and Sundar Kanthadai in 2014 and is headquartered in San Jose, CA. | Packaged Software | Director/Board Member | |
X-Vax Technology, Inc.
X-Vax Technology, Inc. BiotechnologyHealth Technology X-Vax Technology, Inc. operates as a biotechnology company. The company was founded in 2015 and is headquartered in New York, NY. | Biotechnology | Director/Board Member | |
Silicon INSITE, Inc.
Silicon INSITE, Inc. BiotechnologyHealth Technology Silicon Therapeutics LLC operates as an integrated computational drug discovery company that focuses on developing novel medicines for diseases. Its INSITE platform closely represents the dynamical nature of targets using all-atom simulations. The firm has offices in Boston and Shanghai. The company was founded by Lijun Sun, Peiqi Sun, Elliot L. Chaikof, and Finith Jernigan, III in 2016 and is headquartered in Boston, MA. | Biotechnology | Chairman | |
SECULETTER CO., LTD. | Packaged Software | Director/Board Member | |
PDC Line Pharma SASU
PDC Line Pharma SASU Pharmaceuticals: MajorHealth Technology PDC Line Pharma SASU develops an active immuno-therapies for cancer based on an allogeneic cell line of Plasmacytoid Dendritic cells (PDC line) loaded with cancer antigens. It offers PDC line which displays antigen presenting cell abilities allowing the priming of antitumor na?ve CD8+ cells in vitro and in vivo (humanized mouse model). The company was founded by Laurent Levy and Joel Plumas in April 2014 and is headquartered in Grenoble, France. | Pharmaceuticals: Major | Director/Board Member | |
Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | Biotechnology | Chairman | |
Janssen Therapeutics, Inc. | President | ||
Prolor Biotech Ltd.
Prolor Biotech Ltd. BiotechnologyHealth Technology Prolor Biotech Ltd. develops proprietary versions of already-approved therapeutic proteins. The private company is based in Nes Ziona, Israel. | Biotechnology | Chief Executive Officer Corporate Officer/Principal | |
Prokarium Ltd.
Prokarium Ltd. Miscellaneous Commercial ServicesCommercial Services Prokarium Ltd. operates as a biopharmaceutical company that focuses on developing vaccination solutions based on synthetic biology. Its oral vaccine delivery platform Vaxonella stimulates broad protective immune responses applicable to a wide range of diseases. The company is headquartered in Keele, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member | |
Geneos Therapeutics, Inc.
Geneos Therapeutics, Inc. BiotechnologyHealth Technology Geneos Therapeutics, Inc. Develops and commercializes neo-antigen based personalized cancer therapies. The firm engages in developing personalized immunotherapies against tumor specific neoantigens which arise from gene mutations in cancerous cells. The company was founded by Niranjan Y. Sardesai in 2017 and is headquartered in Plymouth Meeting, PA. | Biotechnology | Director/Board Member | |
Pomerantz Life Sciences Consulting Group LLC | President | ||
Terragenic International Ltd. | Chairman | ||
VIRACTA THERAPEUTICS, INC. | Biotechnology | Chairman | |
Aprinoia Therapeutics, Inc. /US/
Aprinoia Therapeutics, Inc. /US/ BiotechnologyHealth Technology Aprinoia Therapeutics, Inc. operates as a global clinical-stage biopharmaceutical company. It develops imaging diagnostic tools, targeted therapy drugs, and other products. The company was founded in 2015 and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member | |
Silicon Therapeutics, Inc. | Chairman | ||
Verimmune, Inc.
Verimmune, Inc. BiotechnologyHealth Technology Verimmune, Inc. is a company based in Washington that is dedicated to developing a first-in-class cancer immunotherapy called anti-tumor immune redirection (AIR). Verimmune's proprietary virus-inspired particle (VIP) technology platform redirects pre-existing pathogenic or childhood vaccine immune memory toward tumors. The American company's lead immuno-oncology product candidate, Veri-101, harnesses the cellular immune memory responses from prior cytomegalovirus (CMV) infection to fight cancer. This mechanism of action has the potential to redefine the treatment paradigm for patients with untreatable cancers or resistance to existing therapies. The company was founded in 1995 by John Troyer and Joshua Weiyuan Wang, with Joshua Weiyuan Wang serving as the CEO since then. | Biotechnology | Director/Board Member | |
INDAPTUS THERAPEUTICS, INC. | Pharmaceuticals: Major | Chairman | |
Technion Institute | College/University | Undergraduate Degree |
Statistiques
Internationale
Etats-Unis | 25 |
Israël | 14 |
Royaume-Uni | 4 |
Irlande | 3 |
Corée du Sud | 3 |
Sectorielle
Health Technology | 25 |
Consumer Services | 12 |
Commercial Services | 3 |
Health Services | 3 |
Finance | 3 |
Opérationnelle
Director/Board Member | 78 |
Corporate Officer/Principal | 22 |
Independent Dir/Board Member | 20 |
Chairman | 19 |
Chief Executive Officer | 13 |
Relations les plus connectées
Insiders | |
---|---|
Roger Pomerantz | 30 |
Michel Moise Habib | 23 |
Bernhard Kirschbaum | 15 |
Avri Havron | 14 |
Shai Novik | 13 |
Sangwoo Lee | 12 |
Gili Hart | 11 |
Brian Schwartz | 9 |
Andrew Singer | 9 |
Oren Elmaliah | 6 |
Baruch Halpert | 4 |
Dror Mevorach | 4 |
Oren Hershkovitz | 3 |
Einat Galamidi | 3 |
Shmuel Hess | 2 |
- Bourse
- Insiders
- Shachar Shlosberger
- Connexions Sociétés